Accès ouvert · CC BY

New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirin

Article scientifique 2022 Sciences de la santé Anglais

Résumé

Background : Several studies have resulted in controversial data about the recurrence or new incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C who were treated with direct-acting antivirals (DAAs). Aim: This observational study aimed to assess the occurrence rate of HCC in patients who developed a sustained virological response (SVR).. METHOD : A six-month prospective study was done at the National Hepatology and Tropical Medicine Research Institute [NHTMRI] in Cairo, Egypt on 150 chronic hepatitis C (CHC) patients treated with sofosbuvir and daclatasvir with or without ribavirin. Patients were assigned into two groups according to their laboratory values to either receive sofosbuvir/daclatasvir and ribavirin (S/D/R) or receive only sofosbuvir/daclatasvir (S/D). The main outcome measure was the occurrence of HCC. Results : SVR-12 was 100%. 8.5% of patients developed HCC in the S/D/R group, while 0% in the S/D group. Conclusion: New incidence or recurrence of HCC may occur in CHC genotype 4 cirrhotic patients receiving sofosbuvir/daclatasvir and ribavirin (difficult to treat) although achieving SVR. The cause of HCC development in this study is cirrhosis, not the administered DAAs.

Citer ce document

Essawy, A., Mehrez, M., Shaheen, S. M., Garem, H. E., & Sabri, N. A. (2022). New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirin. F1000Research. https://doi.org/10.12688/f1000research.73076.2

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 06/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 15

Téléchargements (hors robots) : 0

Méthode de comptage